糖尿病黄斑水肿抗血管内皮生长因子治疗进展

Update on anti-vascular endothelial growth factor treatment for diabetic macular edema

糖尿病黄斑水肿(DME)是导致糖尿病患者视功能损伤的主要原因之一,DME的治疗方法包括激光光凝治疗、抗炎治疗和抗血管内皮生长因子(VEGF)治疗。近年来,抗VEGF药物Ranibizumab、Bevacizumab、VEGF-Trap和KH902等对DME有良好的治疗效果。文章对DME抗VEGF治疗进展进行综述,探讨抗VEGF治疗的有效性和安全性。

Diabetic macular edema（DME） is one of the major causes of visual impairment in patients with diabetes mellitus.The major treatment methods for DME include laser photocoagulation therapy,anti-inflammatory therapy and anti-vascular endothelial growth factor（VEGF） therapy.In recent years,anti-VEGF drugs such as Ranibizumab,Bevacizumab,VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME.The research progress of anti-VEGF therapy for DME is reviewed in this paper,and the efficacy and safety of anti-VEGF therapy are explored.